PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

Korábbi kezelés

• Patient who present with common contraindications for surgery related to patient status

Más betegség

• Patient who present with common contraindications for surgery related to disease extension

Egyéb

• Patient who present with stage I or stage IIA (including T2 N0 M0) or stage IV
• Patient who present with common contraindication to radiochemotherapy with either fluorouracile-cisplatin or with paclitaxel-carboplatin

• Resectable and operable esophageal cancer located under the carena (beyond 25 cm from the incisors) or junctional cancer (Siewert I or II)
• Invasive adenocarcinoma or squamous cell type (to stick to the population included in the CROSS trial)
• Patient who present with:
  • stage IIA (T3N0M0)
  • stage IIB (T1 N1 M0 or T2 N1 M0),
  • stage III (T3 N1 M0 or T4 N0 N1 M0) tumors
• ECOG performance status 0, 1 or 2
• Patient eligible for preoperative chemoradiation with either fluorouracil- oxaliplatin-folinic acid, or Paclitaxel-carboplatin
• Age ≥ 18
• Peripheral neuropathy ≤ NCI-CTC grade 1
• Adequate bone marrow reserve, normal renal and liver functions:
  • Neutrophil count ≥ 1500/mm3
  • Platelet count ≥ 100 000/mm3
  • Hemoglobin ≥ 10 g/dl (after transfusion, if necessary)
  • Creatinin < 15mg/L
  • Clearance of creatinin (Cockcroft formulae) ≥ 60 ml/mn
  • Prothrombin time ≥ 60%
  • ASAT-ALAT ≤2.5 x ULN
  • Total bilirubin < 1.5 x ULN
  • Albumin greater the lower limit of normal
• Start of treatment within 28 days after randomization
• Negative pregnancy test (serum beta-HCG) performed within 1 week prior to start of study treatment in females with reproductive potential
• Patient covered by government health insurance
• Patient who provide a signed written informed consent form